Krystal Biotech vs MeiraGTx
KRYS and MGTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KRYS and MGTX compare
Krystal Biotech is the larger company, worth 10 times as much as MeiraGTx ($9.0B against $882M).
On earnings, MeiraGTx is cheaper: it trades at 11.5× trailing earnings, against 41.4× for Krystal Biotech.
MeiraGTx grew revenue faster over the last twelve months (1366% versus 26.0% for Krystal Biotech).
Krystal Biotech keeps more of each dollar of sales as profit, with a net margin of 47.9% compared with 19.5% at MeiraGTx.
Krystal Biotech scores higher on the StockData Score (11 against 10 for MeiraGTx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KRYS | MGTX |
|---|---|---|
| Size and price | ||
| Market cap | $9.0B | $882M |
| Share price | $305.23 | $9.18 |
| Change, 1 year | 50.3% | 6.0% |
| Change, 5 years | 483% | −50.8% |
| Beta (5Y) | 0.84 | 1.58 |
| Employees | 295 | 403 |
| StockData Score | ||
| Total score | 11 (better) | 10 |
| Valuation score | 1 | 4 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 41.4× | 11.5× (better) |
| P/S | 19.2× | 2.2× (better) |
| P/B | 6.3× | – |
| EV/EBITDA | 35.7× | 4.3× (better) |
| P/FCF | 29.1× | – |
| FCF yield | 3.4% (better) | −0.34% |
| Fair value | $214.74 | $27.21 |
| Margin of safety | −42.1% | 66.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 26.0% | 1366% (better) |
| Revenue growth, 5Y average | – | 39.2% |
| Net income growth (TTM) | 13.2% | – |
| EPS growth (TTM) | 10.5% | – |
| Profitability | ||
| Operating margin | 48.4% (better) | 44.8% |
| Net margin | 47.9% (better) | 19.5% |
| FCF margin | 66.0% (better) | −0.74% |
| Return on equity | 17.5% | – |
| Return on invested capital | 42.6% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Net debt / EBITDA | – | −0.33 |
| Current ratio | 7.89 (better) | 4.62 |
| Altman Z-score | 37.71 (better) | 3.11 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −20.0% |
| Shareholder yield | 0.00% (better) | −20.0% |
| Ownership | ||
| Held by institutions | 102% | 82.5% |
| Held by insiders | 17.2% | 35.2% |
| Insider net buying, 12 months | −$105M | −$4.7M (better) |
| Short interest, % of float | 12.4% | 10.7% |
Go deeper
- KRYS stock overview
- KRYS income statement
- KRYS valuation and score
- MGTX stock overview
- MGTX income statement
- MGTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.